Iconovo

The European Patent Office (EPO) has issued an Intention to Grant for a patent application related to ICOres®, which means that Iconovo will receive a new patent for the inhaler in the EU protecting it until 2038 after a series of administrative steps have been completed. ICOres® is already protected by patents in Europe, Sweden, India, Japan and the United States.

"The preliminary notification from the European Patent Office strengthens our intellectual property rights for ICOres in the EU and thereby increases the value of our product portfolio. The first ICOres product expected to be launched in the EU is based on the drugs budesonide and formoterol and is being developed by our partner Amneal as a generic version of the bestseller Symbicort® Turbuhaler®. Amneal's latest pharmacokinetic pilot study indicates that the product's properties would enable the achievement of the criteria for bioequivalence in a pivotal study, and we look forward to this important step on the road to a potential market launch," says Iconovo's CEO, Johan Wäborg.

About ICOres®
ICOres® is a multidose dry powder inhaler developed by Iconovo. The inhaler is operated in the same way as AstraZeneca's bestseller Turbuhaler® and contains two separate reservoirs, making it particularly well suited for combination products. ICOres® has several unique features and functions that increase ease of use. A dose counter shows exactly how many doses remain and visual feedback informs the user when the dose is ready for inhalation and when it has been inhaled correctly.